"CLOVIBACTIN: A LITERATURE REVIEW OF A NEW ANTIBIOTIC EXPECTED TO OVERCOME RESISTANCE MENGATASI RESISTENSI"
Abstract
This review discusses about that Clovibactin is a new antibiotic isolated from soil samples in the state of North Carolina. Clovibactin contains eight depsipeptide residues consisting of a macrolactone ring and a linear tail. This antibiotic is active against gram-positive bacteria, including drug-resistant human pathogens such as Methicillin-resistant Staphylococcus aureus, Vancomycin-resistant enterococci, dan Mycobacterium.tuberculosis. This review aims to assess the activity of clovibactin against Mycobacterium tuberculosis. Clovibactin works by inhibiting all cell wall biosynthesis reactions that consume lipid I, lipid II, lipid IIIwall teichoic acid or undecaprenyl-pyrophosphate (C55PP). Clovibactin showed no cytotoxicity to National Institute of Health/3T3 and HepG2 cells in mammals at a dose of 100 µg/mL. Clovibactin has bactericidal properties on gram-positive bacteria. Clovibactin has an MIC of 0.5-1 µg/mL on M.tuberculosis so it has good bactericidal efficacy with low toxicity.
Keywords:
Clovibactin, Antibiotic, Drug resistant, Bacteria
References
[1] L. L. Ling et al., “A new antibiotic kills pathogens without detectable resistance,” Nature, vol. 517, no. 7535, pp. 455–459, Jan. 2015, doi: 10.1038/nature14098.
[2] P. M. Ndaki, J. R. Mwanga, M. F. Mushi, E. T. Konje, S. M. Mwita, and S. E. Mshana, “Drivers of inappropriate use of antibiotics among community members in low- and middle-income countries: a systematic review of qualitative studies,” BMC Public Health, vol. 25, no. 1, Dec. 2025, doi: 10.1186/s12889-025-21553-6.
[3] Sugiah, Fadli, F. Hariati, and K. A. Cendekiawan, “Antibiotics And Bacterial Resistance: A Global Challenge That Needs To Be Addressed,” Pharmacopoeia Pharmacy Journal, vol. 2, pp. 3047–4469, 2025, doi: https://doi.org/10.62872/v3yvk866.
[4] J. Quigley et al., “Novel antimicrobials from uncultured bacteria acting against mycobacterium tuberculosis,” mBio, vol. 11, no. 4, pp. 1–13, 2020, doi: 10.1128/mBio.01516-20.
[5] O. Sierra-Hernandez et al., “In Silico Identification of Potential Clovibactin-like Antibiotics Binding to Unique Cell Wall Precursors in Diverse Gram-Positive Bacterial Strains,” Int J Mol Sci, vol. 26, no. 4, Feb. 2025, doi: 10.3390/ijms26041724.
[6] M. Krumberger et al., “Synthesis and Stereochemical Determination of the Peptide Antibiotic Novo29,” Journal of Organic Chemistry, vol. 88, no. 4, pp. 2214–2220, Feb. 2023, doi: 10.1021/acs.joc.2c02648.
[7] C. T. Kahrstrom, “A new drug for resistant bugs,” Nature review microbiology, vol. 13, pp. 126–127, Jan. 2015, Accessed: Jul. 04, 2025. [Online]. Available: https://www.nature.com/articles/nrmicro3429
[8] P. Hunter, “Antibiotic discovery goes underground,” EMBO Rep, vol. 16, no. 5, pp. 563–565, May 2015, doi: 10.15252/embr.201540385.
[9] R. Shukla et al., “An antibiotic from an uncultured bacterium binds to an immutable target,” Cell, vol. 186, no. 19, pp. 4059-4073.e27, Sep. 2023, doi: 10.1016/j.cell.2023.07.038.
[10] C. D. Fage et al., “The Kalimantacin Polyketide Antibiotics Inhibit Fatty Acid Biosynthesis in Staphylococcus aureus by Targeting the Enoyl-Acyl Carrier Protein Binding Site of FabI,” Angewandte Chemie - International Edition, vol. 59, no. 26, pp. 10549–10556, Jun. 2020, doi: 10.1002/anie.201915407.
[11] N. Shahsavari et al., “A Silent Operon of Photorhabdus luminescens Encodes a Prodrug Mimic of GTP,” mBio, vol. 13, no. 3, Jun. 2022, doi: 10.1128/mbio.00700-22.
[12] S. S. Adeiza, “ Clovibactin and Staphylococcus aureus: a new weapon against resistant strains,” GMSHygiene and Infection Control , vol. 19, pp. 1–9, 2024.
[13] T. Homma et al., “Dual targeting of cell wall precursors by teixobactin leads to cell lysis,” Antimicrob Agents Chemother, vol. 60, no. 11, pp. 6510–6517, Nov. 2016, doi: 10.1128/AAC.01050-16.
[14] S. Mahapatra, H. Scherman, P. J. Brennan, and D. C. Crick, “N glycolylation of the nucleotide precursors of peptidoglycan biosynthesis of Mycobacterium spp. is altered by drug treatment,” J Bacteriol, vol. 187, no. 7, pp. 2341–2347, Apr. 2005, doi: 10.1128/JB.187.7.2341-2347.2005.
[15] P. J. Stogios and A. Savchenko, “Molecular mechanisms of vancomycin resistance,” Mar. 01, 2020, Blackwell Publishing Ltd. doi: 10.1002/pro.3819.
[16] A. M. Perez-Moreno, P. Torres, and J. L. Paris, “Clovibactin: Discovery and antimicrobial mechanism of action,” European Journal of Allergy and Clinical Immunology, vol. 79, no. 8, pp. 2302–2304, Apr. 2024.
[17] C. M. Kobras, S. M. Morris, T. Mascher, and S. Gebhard, “Application of a Bacillus subtilis Whole-Cell Biosensor (PliaI-lux) for the Identification of Cell Wall Active Antibacterial Compounds,” Methods Mol Biol, vol. 2601, pp. 259–270, 2023.
[18] W. D. Fiers, M. Craighead, and I. Singh, “Teixobactin and Its Analogues: A New Hope in Antibiotic Discovery,” Oct. 13, 2017, American Chemical Society. doi: 10.1021/acsinfecdis.7b00108.
[19] L. J. V. Piddock, “Teixobactin, the first of a new class of antibiotics discovered by ichip technology?,” Journal of Antimicrobial Chemotherapy, vol. 70, no. 10, pp. 2679–2680, Oct. 2015, doi: 10.1093/jac/dkv175.
[20] D. P. Baquero et al., “Extracellular cytochrome nanowires appear to be ubiquitous in prokaryotes,” Cell, vol. 186, no. 13, pp. 2853-2864.e8, Jun. 2023, doi: 10.1016/j.cell.2023.05.012.
[21] J. Wu, R. Mu, Z. J. Liu, S. C. Lu, and G. Liu, “Scalable total synthesis of a mycobactin T analogue utilizing a novel synthetic and protection strategy,” Organic Chemistry Frontiers, vol. 6, no. 14, pp. 2467–2470, 2019, doi: 10.1039/c9qo00502a.
[2] P. M. Ndaki, J. R. Mwanga, M. F. Mushi, E. T. Konje, S. M. Mwita, and S. E. Mshana, “Drivers of inappropriate use of antibiotics among community members in low- and middle-income countries: a systematic review of qualitative studies,” BMC Public Health, vol. 25, no. 1, Dec. 2025, doi: 10.1186/s12889-025-21553-6.
[3] Sugiah, Fadli, F. Hariati, and K. A. Cendekiawan, “Antibiotics And Bacterial Resistance: A Global Challenge That Needs To Be Addressed,” Pharmacopoeia Pharmacy Journal, vol. 2, pp. 3047–4469, 2025, doi: https://doi.org/10.62872/v3yvk866.
[4] J. Quigley et al., “Novel antimicrobials from uncultured bacteria acting against mycobacterium tuberculosis,” mBio, vol. 11, no. 4, pp. 1–13, 2020, doi: 10.1128/mBio.01516-20.
[5] O. Sierra-Hernandez et al., “In Silico Identification of Potential Clovibactin-like Antibiotics Binding to Unique Cell Wall Precursors in Diverse Gram-Positive Bacterial Strains,” Int J Mol Sci, vol. 26, no. 4, Feb. 2025, doi: 10.3390/ijms26041724.
[6] M. Krumberger et al., “Synthesis and Stereochemical Determination of the Peptide Antibiotic Novo29,” Journal of Organic Chemistry, vol. 88, no. 4, pp. 2214–2220, Feb. 2023, doi: 10.1021/acs.joc.2c02648.
[7] C. T. Kahrstrom, “A new drug for resistant bugs,” Nature review microbiology, vol. 13, pp. 126–127, Jan. 2015, Accessed: Jul. 04, 2025. [Online]. Available: https://www.nature.com/articles/nrmicro3429
[8] P. Hunter, “Antibiotic discovery goes underground,” EMBO Rep, vol. 16, no. 5, pp. 563–565, May 2015, doi: 10.15252/embr.201540385.
[9] R. Shukla et al., “An antibiotic from an uncultured bacterium binds to an immutable target,” Cell, vol. 186, no. 19, pp. 4059-4073.e27, Sep. 2023, doi: 10.1016/j.cell.2023.07.038.
[10] C. D. Fage et al., “The Kalimantacin Polyketide Antibiotics Inhibit Fatty Acid Biosynthesis in Staphylococcus aureus by Targeting the Enoyl-Acyl Carrier Protein Binding Site of FabI,” Angewandte Chemie - International Edition, vol. 59, no. 26, pp. 10549–10556, Jun. 2020, doi: 10.1002/anie.201915407.
[11] N. Shahsavari et al., “A Silent Operon of Photorhabdus luminescens Encodes a Prodrug Mimic of GTP,” mBio, vol. 13, no. 3, Jun. 2022, doi: 10.1128/mbio.00700-22.
[12] S. S. Adeiza, “ Clovibactin and Staphylococcus aureus: a new weapon against resistant strains,” GMSHygiene and Infection Control , vol. 19, pp. 1–9, 2024.
[13] T. Homma et al., “Dual targeting of cell wall precursors by teixobactin leads to cell lysis,” Antimicrob Agents Chemother, vol. 60, no. 11, pp. 6510–6517, Nov. 2016, doi: 10.1128/AAC.01050-16.
[14] S. Mahapatra, H. Scherman, P. J. Brennan, and D. C. Crick, “N glycolylation of the nucleotide precursors of peptidoglycan biosynthesis of Mycobacterium spp. is altered by drug treatment,” J Bacteriol, vol. 187, no. 7, pp. 2341–2347, Apr. 2005, doi: 10.1128/JB.187.7.2341-2347.2005.
[15] P. J. Stogios and A. Savchenko, “Molecular mechanisms of vancomycin resistance,” Mar. 01, 2020, Blackwell Publishing Ltd. doi: 10.1002/pro.3819.
[16] A. M. Perez-Moreno, P. Torres, and J. L. Paris, “Clovibactin: Discovery and antimicrobial mechanism of action,” European Journal of Allergy and Clinical Immunology, vol. 79, no. 8, pp. 2302–2304, Apr. 2024.
[17] C. M. Kobras, S. M. Morris, T. Mascher, and S. Gebhard, “Application of a Bacillus subtilis Whole-Cell Biosensor (PliaI-lux) for the Identification of Cell Wall Active Antibacterial Compounds,” Methods Mol Biol, vol. 2601, pp. 259–270, 2023.
[18] W. D. Fiers, M. Craighead, and I. Singh, “Teixobactin and Its Analogues: A New Hope in Antibiotic Discovery,” Oct. 13, 2017, American Chemical Society. doi: 10.1021/acsinfecdis.7b00108.
[19] L. J. V. Piddock, “Teixobactin, the first of a new class of antibiotics discovered by ichip technology?,” Journal of Antimicrobial Chemotherapy, vol. 70, no. 10, pp. 2679–2680, Oct. 2015, doi: 10.1093/jac/dkv175.
[20] D. P. Baquero et al., “Extracellular cytochrome nanowires appear to be ubiquitous in prokaryotes,” Cell, vol. 186, no. 13, pp. 2853-2864.e8, Jun. 2023, doi: 10.1016/j.cell.2023.05.012.
[21] J. Wu, R. Mu, Z. J. Liu, S. C. Lu, and G. Liu, “Scalable total synthesis of a mycobactin T analogue utilizing a novel synthetic and protection strategy,” Organic Chemistry Frontiers, vol. 6, no. 14, pp. 2467–2470, 2019, doi: 10.1039/c9qo00502a.
Published
2025-11-28
Section
Articles
2.jpg)
